IMPL - Impel NeuroPharma, Inc. Stock Price, Fair Value and News

0.02USD+0.01 (+100.00%)Delayed

Market Summary

USD0.02+0.01

Delayed

100.00%

IMPL Stock Price

View Fullscreen

IMPL RSI Chart

IMPL Valuation

Market Cap

478.0K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.02

EV/EBITDA

Price/Free Cashflow

-0.01

IMPL Price/Sales (Trailing)

IMPL Profitability

Operating Margin

52.58%

EBT Margin

-353.93%

Return on Equity

-1.9K%

Return on Assets

-211.78%

Free Cashflow Yield

-17.1K%

IMPL Fundamentals

IMPL Revenue

Revenue (TTM)

21.0M

Rev. Growth (Yr)

62.98%

Rev. Growth (Qtr)

-23.71%

IMPL Earnings

Earnings (TTM)

-74.3M

Earnings Growth (Yr)

55.58%

Earnings Growth (Qtr)

-87.77%

Breaking Down IMPL Revenue

Last 7 days

-50%

Last 30 days

-90%

Last 90 days

-95.4%

Trailing 12 Months

-99.7%

How does IMPL drawdown profile look like?

IMPL Financial Health

Current Ratio

0.19

IMPL Investor Care

Shares Dilution (1Y)

0.68%

Diluted EPS (TTM)

-3.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	15.3M	19.0M	21.0M	0
2022	3.7M	6.7M	9.7M	12.7M
2021	0	0	0	668.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Impel NeuroPharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 19, 2023	vivo capital viii, llc	sold	-16,692	0.08	-208,657	-
Dec 19, 2023	vivo capital viii, llc	sold	-2,290	0.08	-28,632	-
Dec 18, 2023	vivo capital viii, llc	sold	-3,155	0.11	-28,682	-
Dec 18, 2023	vivo capital viii, llc	sold	-22,993	0.11	-209,029	-
Dec 15, 2023	vivo capital viii, llc	sold	-25,500	0.29	-87,934	-
Dec 15, 2023	vivo capital viii, llc	sold	-3,499	0.29	-12,066	-
Dec 31, 2022	leaman john harold	sold (taxes)	-13,601	3.75	-3,627	chief fin. & business officer
Dec 31, 2022	leaman john harold	acquired	-	-	10,571	chief fin. & business officer
Mar 29, 2022	shrewsbury stephen b	acquired	48,473	1.97	24,606	chief medical officer
Dec 22, 2021	hoekman john	acquired	32,800	1.64	20,000	chief scientific officer

Which funds bought or sold IMPL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	venBio Partners LLC	sold off	-100	-340,834	-	-%
Apr 02, 2024	ST GERMAIN D J CO INC	sold off	-100	-185	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-7,000	-	-%
Feb 13, 2023	TRUSTCORE FINANCIAL SERVICES, LLC	added	7.46	-10,974	54,026	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	5,000	5,000	-%

Are Funds Buying or Selling IMPL?

Are funds buying IMPL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMPL

No. of Funds

Unveiling Impel NeuroPharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 04, 2023	oaktree capital group, llc	0.13%	34,162	SC 13D/A
Nov 15, 2023	oaktree capital group, llc	0.11%	29,282	SC 13D/A
Oct 06, 2023	oaktree capital group, llc	0.09%	24,402	SC 13D/A
Sep 15, 2023	oaktree capital group, llc	0.06%	14,641	SC 13D

Recent SEC filings of Impel NeuroPharma, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Mar 26, 2024	15-12G	15-12G
Mar 12, 2024	8-K	Current Report
Feb 15, 2024	EFFECT	EFFECT
Feb 14, 2024	S-8 POS	Employee Benefits Plan
Feb 14, 2024	S-8 POS	Employee Benefits Plan
Feb 14, 2024	S-8 POS	Employee Benefits Plan
Feb 14, 2024	POS AM	POS AM

Peers (Alternatives to Impel NeuroPharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Impel NeuroPharma, Inc. News

Latest updates

Impel NeuroPharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-23.7%	5,023,000	6,584,000	4,372,000	5,008,000	3,082,000	2,803,000	1,759,000	925,000	91,000
Cost Of Revenue	-30.7%	2,230,000	3,220,000	2,285,000	2,217,500	1,508,000	1,737,000	1,033,000	441,000	250,000
Gross Profit	-17.0%	2,793,000	3,364,000	2,087,000	2,790,500	1,574,000	1,066,000	726,000	182,000	-159,000
Operating Expenses	-19.8%	15,604,000	19,468,000	26,523,000	21,032,000	22,814,000	22,046,000	23,449,000	24,389,000	22,267,000
S&GA Expenses	-20.3%	15,352,000	19,268,000	22,037,000	20,332,000	19,659,000	18,095,000	19,799,000	20,053,000	16,338,000
R&D Expenses	26.0%	252,000	200,000	3,003,000	700,000	3,155,000	3,951,000	3,650,000	4,336,000	5,929,000
EBITDA Margin	24.4%	-4.07	-5.39	-7.90	-9.40	-12.30	-16.80	-27.11	-119	-
Interest Expenses	-21.4%	-3,661,000	-3,015,000	-2,933,000	-2,766,000	-3,192,000	-3,450,000	-4,427,000	-881,500	-2,420,000
Income Taxes	-	-	-	-	-	-	-	-	2,000	-
Earnings Before Taxes	-87.8%	-13,814,000	-7,357,000	-30,067,000	-23,041,000	-31,097,000	-25,204,000	-26,970,000	-24,740,000	-25,021,000
EBT Margin	26.4%	-3.54	-4.81	-7.17	-8.40	-11.19	-15.31	-25.17	-114	-
Net Income	-87.8%	-13,814,000	-7,357,000	-30,067,000	-23,041,000	-31,097,000	-25,204,000	-26,970,000	-24,742,000	-25,021,000
Net Income Margin	26.4%	-3.54	-4.81	-7.17	-8.40	-11.19	-15.31	-25.17	-114	-
Free Cashflow	13.9%	-17,481,000	-20,308,000	-25,189,000	-18,998,000	-22,828,000	-28,974,000	-24,219,000	-23,338,000	-17,374,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-21.7%	35.00	45.00	65.00	89.00	105	120	148	98.00	121	69.00	11.00	12.00	42.00
Current Assets	-28.8%	23.00	33.00	52.00	80.00	99.00	114	142	95.00	118	66.00	6.00	8.00	40.00
Cash Equivalents	-98.4%	0.00	15.00	36.00	61.00	80.00	98.00	130	88.00	111	61.00	4.00	7.00	37.00
Inventory	-1.7%	7.00	7.00	8.00	8.00	9.00	7.00	5.00	3.00	2.00	-	-	-	-
Net PPE	3.6%	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	3.00
Liabilities	2.4%	127	124	138	133	127	117	120	45.00	46.00	18.00	29.00	19.00	8.00
Current Liabilities	2.9%	125	121	22.00	22.00	20.00	18.00	24.00	16.00	16.00	9.00	13.00	11.00	8.00
Long Term Debt	-	-	-	48.00	48.00	47.00	47.00	47.00	29.00	29.00	9.00	7.00	8.00	-
LT Debt, Current	132.1%	111	48.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	48.00	48.00	47.00	47.00	47.00	29.00	29.00	9.00	7.00	8.00	-
Shareholder's Equity	-	-	-	-	-	-	4.00	27.00	53.00	76.00	51.00	-	-	-
Retained Earnings	-3.9%	-372	-358	-351	-321	-298	-266	-241	-214	-190	-165	150	-138	-92.46
Additional Paid-In Capital	0.4%	280	279	278	277	276	271	269	267	266	216	5.00	5.00	1.00
Shares Outstanding	0%	24.00	24.00	24.00	24.00	23.00	23.00	23.00	23.00	12.00	7.00	1.00	1.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	19.2%	-16,524	-20,440	-24,143	-17,986	-22,678	-28,767	-24,211	-23,194	-17,226	-16,034	-9,910	-10,296	-9,567	-8,689	-10,631	-
Share Based Compensation	-2.9%	1,067	1,099	1,319	1,252	565	1,579	1,795	1,103	978	556	493	426	432	2,485	298	-
Cashflow From Investing	-825.0%	-957	132	-1,046	-1,012	-150	-207	-8.00	-144	-148	-89.00	-27.00	-889	-75.00	-400	-418	-
Cashflow From Financing	141100.0%	7,060	5.00	-	-79.00	4,732	-3,036	65,844	261	67,715	72,604	7,309	9,992	1,041	18.00	8.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IMPL Income Statement

2023-09-30

Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Product revenue, net	$ 5,023	$ 3,082	$ 15,979	$ 7,644
Cost of goods sold	2,230	1,508	7,734	4,277
Gross profit	2,793	1,574	8,245	3,367
Operating expenses:
Research and development	252	3,155	3,456	10,756
Selling, general and administrative	15,352	19,659	56,659	57,553
Restructuring	0	0	1,481	0
Total operating expenses	15,604	22,814	61,596	68,309
Loss from operations	(12,811)	(21,240)	(53,351)	(64,942)
Other income (expense), net :
Interest income (expense), net	(3,661)	(3,192)	(9,609)	(11,069)
Other income (expense), net	2,658	(6,665)	11,722	(7,260)
Total other income (expense), net	(1,003)	(9,857)	2,113	(18,329)
Loss before income taxes	(13,814)	(31,097)	(51,238)	(83,271)
Provision (benefit) for income taxes	0	0	0	0
Net loss and comprehensive loss	$ (13,814)	$ (31,097)	$ (51,238)	$ (83,271)
Net loss per share - basic	$ (0.58)	$ (1.31)	$ (2.16)	$ (3.57)
Net loss per share - diluted	$ (0.58)	$ (1.31)	$ (2.16)	$ (3.57)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	23,749,005	23,709,546	23,747,640	23,345,946
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	23,749,005	23,709,546	23,747,640	23,345,946

IMPL Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheet (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 239	$ 60,654
Restricted cash	4,502	0
Trade receivables, net	6,586	7,444
Inventory	6,864	8,427
Prepaid expenses and other current assets	5,236	3,284
Total current assets	23,427	79,809
Property and equipment, net	4,087	3,863
Operating lease right-of-use assets	3,730	3,132
Other assets	3,829	1,746
Total assets	35,073	88,550
Current liabilities:
Accounts payable	3,734	6,092
Accrued and other liabilities	8,446	12,503
Current portion of long-term debt	111,001	0
Current portion of deferred royalty obligation	0	2,027
Current portion of operating lease liability	1,562	1,541
Total current liabilities	124,743	22,163
Operating lease liability, net of current portion	2,235	1,573
Deferred royalty obligation, net of current portion	0	60,899
Long-term debt	0	48,072
Total liabilities	126,978	132,707
Commitments and contingencies (Note 6)
Stockholders '(deficit) equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized: none issued	0	0
Common stock, $0.001 par value; 300,000,000 shares authorized; 23,749,005 and 23,739,313 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	24	24
Additional paid-in capital	280,419	276,929
Accumulated deficit	(372,348)	(321,110)
Total stockholders' deficit	(91,905)	(44,157)
Total liabilities and stockholders' deficit	$ 35,073	$ 88,550

About Impel NeuroPharma, Inc.

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

CEO	Mr. Adrian Adams
WEBSITE	https://impelpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	160

Impel NeuroPharma, Inc. Frequently Asked Questions

What is the ticker symbol for Impel NeuroPharma, Inc.? What does IMPL stand for in stocks?

IMPL is the stock ticker symbol of Impel NeuroPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Impel NeuroPharma, Inc. (IMPL)?

As of Thu Feb 15 2024, market cap of Impel NeuroPharma, Inc. is 478 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMPL stock?

You can check IMPL's fair value in chart for subscribers.

What is the fair value of IMPL stock?

You can check IMPL's fair value in chart for subscribers. The fair value of Impel NeuroPharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Impel NeuroPharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMPL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Impel NeuroPharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether IMPL is over valued or under valued. Whether Impel NeuroPharma, Inc. is cheap or expensive depends on the assumptions which impact Impel NeuroPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMPL.

What is Impel NeuroPharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 15 2024, IMPL's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMPL PE ratio will change depending on the future growth rate expectations of investors.